These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

695 related articles for article (PubMed ID: 24222113)

  • 41. BRAF mutations in thyroid tumors from an ethnically diverse group.
    Schulten HJ; Salama S; Al-Mansouri Z; Alotibi R; Al-Ghamdi K; Al-Hamour OA; Sayadi H; Al-Aradati H; Al-Johari A; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J
    Hered Cancer Clin Pract; 2012 Aug; 10(1):10. PubMed ID: 22925390
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Shift in Molecular Drivers of Papillary Thyroid Carcinoma Following the 2017 World Health Organization Classification: Characterization of 554 Consecutive Tumors With Emphasis on BRAF-Negative Cases.
    Hang JF; Chen JY; Kuo PC; Lai HF; Lee TL; Tai SK; Kuo CS; Chen HS; Li WS; Li CF
    Mod Pathol; 2023 Sep; 36(9):100242. PubMed ID: 37307878
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas.
    Erickson LA; Jin L; Nakamura N; Bridges AG; Markovic SN; Lloyd RV
    Cancer; 2007 May; 109(10):1965-71. PubMed ID: 17387744
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns.
    Rivera M; Ricarte-Filho J; Knauf J; Shaha A; Tuttle M; Fagin JA; Ghossein RA
    Mod Pathol; 2010 Sep; 23(9):1191-200. PubMed ID: 20526288
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Changes in the clinicopathological characteristics and genetic alterations of follicular thyroid cancer.
    Song YS; Lim JA; Min HS; Kim MJ; Choi HS; Cho SW; Moon JH; Yi KH; Park DJ; Cho BY; Park YJ
    Eur J Endocrinol; 2017 Dec; 177(6):465-473. PubMed ID: 28864536
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mutation profile of differentiated thyroid tumours in an Australian urban population.
    Mond M; Alexiadis M; Fuller PJ; Gilfillan C
    Intern Med J; 2014 Aug; 44(8):727-34. PubMed ID: 24862939
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Detection of RAS mutation by pyrosequencing in thyroid cytology samples.
    Guerra A; Carrano M; Angrisani E; Puzziello A; Izzo G; Di Crescenzo V; Vatrella A; Vitale M
    Int J Surg; 2014; 12 Suppl 1():S91-4. PubMed ID: 24866065
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma.
    Kim TY; Kim WB; Song JY; Rhee YS; Gong G; Cho YM; Kim SY; Kim SC; Hong SJ; Shong YK
    Clin Endocrinol (Oxf); 2005 Nov; 63(5):588-93. PubMed ID: 16268813
    [TBL] [Abstract][Full Text] [Related]  

  • 49. BRAF in papillary thyroid carcinoma of ovary (struma ovarii).
    Schmidt J; Derr V; Heinrich MC; Crum CP; Fletcher JA; Corless CL; Nosé V
    Am J Surg Pathol; 2007 Sep; 31(9):1337-43. PubMed ID: 17721188
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Discriminating Interpatient Variabilities of RAS Gene Variants for Precision Detection of Thyroid Cancer.
    Fu G; Chazen RS; MacMillan C; Witterick IJ
    JAMA Netw Open; 2024 May; 7(5):e2411919. PubMed ID: 38758552
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Low Prevalence of TERT Promoter, BRAF and RAS Mutations in Papillary Thyroid Cancer in the Greek Population.
    Argyropoulou M; Veskoukis AS; Karanatsiou PM; Manolakelli A; Kostoglou-Athanassiou I; Vilaras G; Karameris A; Liadaki K
    Pathol Oncol Res; 2020 Jan; 26(1):347-354. PubMed ID: 30361901
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association analysis between the interaction of RAS family genes mutations and papillary thyroid carcinoma in the Han Chinese population.
    Jin M; Li Z; Sun Y; Zhang M; Chen X; Zhao H; Yu Q
    Int J Med Sci; 2021; 18(2):441-447. PubMed ID: 33390813
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of different methodologies on the detection of point mutations in routine air-dried fine needle aspiration (FNA) smears.
    Rehfeld C; Münz S; Krogdahl A; Jensen EM; Siebolts U; Ferraz C; Bösenberg E; Hegedüs L; Paschke R; Eszlinger M
    Horm Metab Res; 2013 Jul; 45(7):513-7. PubMed ID: 23508716
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma.
    Baitei EY; Zou M; Al-Mohanna F; Collison K; Alzahrani AS; Farid NR; Meyer B; Shi Y
    J Pathol; 2009 Apr; 217(5):707-15. PubMed ID: 19156774
    [TBL] [Abstract][Full Text] [Related]  

  • 55. RET/PTC rearrangement is prevalent in follicular Hürthle cell carcinomas.
    de Vries MM; Celestino R; Castro P; Eloy C; Máximo V; van der Wal JE; Plukker JT; Links TP; Hofstra RM; Sobrinho-Simões M; Soares P
    Histopathology; 2012 Nov; 61(5):833-43. PubMed ID: 22803838
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Selective occurrence of ras mutations in benign and malignant thyroid follicular neoplasms in Taiwan.
    Liu RT; Hou CY; You HL; Huang CC; Hock-Liew ; Chou FF; Wang PW; Cheng JT
    Thyroid; 2004 Aug; 14(8):616-21. PubMed ID: 15320975
    [TBL] [Abstract][Full Text] [Related]  

  • 57. BRAF and K-RAS mutation in a Greek papillary and medullary thyroid carcinoma cohort.
    Goutas N; Vlachodimitropoulos D; Bouka M; Lazaris AC; Nasioulas G; Gazouli M
    Anticancer Res; 2008; 28(1A):305-8. PubMed ID: 18383861
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Relevance of BRAF and NRAS mutations in the primary tumor and metastases of papillary thyroid carcinomas.
    Cañadas-Garre M; Becerra-Massare P; Moreno Casares A; Calleja-Hernández MÁ; Llamas-Elvira JM
    Head Neck; 2016 Dec; 38(12):1772-1779. PubMed ID: 27299298
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
    Santarpia L; Myers JN; Sherman SI; Trimarchi F; Clayman GL; El-Naggar AK
    Cancer; 2010 Jun; 116(12):2974-83. PubMed ID: 20564403
    [TBL] [Abstract][Full Text] [Related]  

  • 60. RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact.
    Volante M; Rapa I; Gandhi M; Bussolati G; Giachino D; Papotti M; Nikiforov YE
    J Clin Endocrinol Metab; 2009 Dec; 94(12):4735-41. PubMed ID: 19837916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.